- Home
- ALVO vs WD Comparison
ALVO vs WD Comparison
Compare ALVO & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- WD
- Stock Information
- Founded
- ALVO 2013
- WD 1937
- Country
- ALVO Luxembourg
- WD United States
- Employees
- ALVO N/A
- WD N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- WD Finance: Consumer Services
- Sector
- ALVO Health Care
- WD Finance
- Exchange
- ALVO Nasdaq
- WD Nasdaq
- Market Cap
- ALVO 2.5B
- WD 2.4B
- IPO Year
- ALVO N/A
- WD 2010
- Fundamental
- Price
- ALVO $9.61
- WD $76.49
- Analyst Decision
- ALVO Buy
- WD Hold
- Analyst Count
- ALVO 1
- WD 3
- Target Price
- ALVO $18.00
- WD $103.33
- AVG Volume (30 Days)
- ALVO 314.4K
- WD 301.0K
- Earning Date
- ALVO 08-14-2025
- WD 08-07-2025
- Dividend Yield
- ALVO N/A
- WD 3.53%
- EPS Growth
- ALVO N/A
- WD 6.51
- EPS
- ALVO 0.34
- WD 2.92
- Revenue
- ALVO $587,890,000.00
- WD $1,056,015,000.00
- Revenue This Year
- ALVO $36.18
- WD $14.45
- Revenue Next Year
- ALVO $42.61
- WD $6.64
- P/E Ratio
- ALVO $28.20
- WD $26.04
- Revenue Growth
- ALVO 413.92
- WD 8.64
- 52 Week Low
- ALVO $7.35
- WD $64.48
- 52 Week High
- ALVO $13.70
- WD $118.19
- Technical
- Relative Strength Index (RSI)
- ALVO 59.59
- WD 60.55
- Support Level
- ALVO $8.51
- WD $71.84
- Resistance Level
- ALVO $8.91
- WD $75.50
- Average True Range (ATR)
- ALVO 0.36
- WD 2.10
- MACD
- ALVO 0.13
- WD 0.16
- Stochastic Oscillator
- ALVO 99.22
- WD 82.89
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.